Molecular Pharmaceutics, Год журнала: 2025, Номер unknown
Опубликована: Май 9, 2025
Intraoperative fluorescence navigation in esophageal cancer enables the clinical translation of imaging. Heat shock protein 90 alpha (Hsp90α) plays a vital role progression malignant disease, and elevated Hsp90α expression has been reported cancer. The aim this study was to develop dual-modality probe, [64Cu]Cu-NOTA-San A-Cy7, for imaging vivo via both positron emission tomography (PET) In study, Hsp90α-targeting cyclopeptide Sansalvamide A (San A) chemically modified with Cy7 dye NOTA chelator simultaneously. Experimental assays confirmed that NOTA-San A-Cy7 favorable affinity Hsp90α-positive EC109 cells, dissociation constant (Kd) 1.08 ± 0.19 μM. probe successfully synthesized 64CuCl2, achieving high radiochemical purity over 95%. Furthermore, demonstrated excellent stability saline serum solutions. subsequently evaluated tumor-bearing model PET imaging, which Hsp90α-specific uptake significantly reduced by co-administration an excess blocking agent. Biodistribution studies revealed at 24 hours post-injection, tumor 1.35 0.29%ID/g nonblocking group decreased 0.73 0.15%ID/g (p < 0.05). Concurrent experiment, conducted, revealing substantial model. As proof concept, imaging-guided surgery utilizing fluorescent component performed. This approach potential providing surgical guidance mice positive Hsp90α, highlighting dual functionality diagnostic intraoperative navigation. summary, our findings unequivocally demonstrate holds significant promise as agent tumors vivo, offering valuable tool detection management such tumors.
Язык: Английский